Research
Hormonal
GLP-1 receptor agonists, SGLT2 inhibitors, and pioglitazone are recommended pharmacotherapies for MASLD/MASH management.
If lifestyle changes are not enough, ask your doctor about GLP-1 RAs, SGLT2 inhibitors, or pioglitazone. These medications can help manage metabolic health and reduce liver disease progression.
GoodSupportsHIGH confidence
Treatment recommendations emphasized a multidisciplinary approach, incorporating lifestyle modifications, pharmacotherapy (including glucagon-like peptide-1 receptor agonists [GLP-1 RA], sodium-glucose cotransporter-2 [SGLT2] inhibitors, and pioglitazone), and surgical interventions when appropriate.
Why this rating
Based on expert consensus and GRADE criteria.
Source
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
Faisal Abaalkhail et al. · Saudi Journal of Gastroenterology · 2025
DOI 10.4103/sjg.sjg_199_25
clinical_guideline · n=15Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.Good
- Bariatric surgery is recommended for eligible patients with noncirrhotic MASLD to achieve sustained weight reduction and remission of type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →